Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

Summary

The hypothesis of this clinical trial is that hepatocellular carcinomas contain somatostatin receptors which make them sensitive to the inhibitory effects of a new somatostatin analog, SOM230. This analog has greater and broader binding affinity to somatostatin receptors compared to the current drug in use, sandostatin LAR. Thus, SOM230 has the potential to be more effective in the treatment of patients with hepatocellular carcinoma.

Timeline

Start

2012-07

Primary completion

2016-08

Completion

2017-02

Drugs

Indications